top of page

Your Patients Ask for a Dementia Vaccine: Most Never Took the One With Early Evidence

Writer: Timothy Agnew
Timothy Agnew
4 days ago
6 min read

Updated: 2 days ago

From three to 18 months after vaccination, people who received the RSV vaccine alone spent 29% more time free of a dementia diagnosis than the flu-vaccine group.


2026 T. Agnew
2026 T. Agnew

Ask patients over 50 whether they would take a vaccine that lowers their dementia risk, and most say yes. A JAMA Network Open survey of 1,529 adults, published on September 21, 2026 said nearly three in four would likely or definitely get one. The vaccine in the survey was hypothetical: several low-cost doses and half the dementia risk for people at high risk.


Meanwhile, a vaccine already in pharmacy refrigerators carries an early dementia signal of its own. It’s the adjuvanted RSV vaccine, and most people who qualify for it haven’t had it. As of February 22, 2026, the CDC put the RSV vaccination at 43.2% of adults 75 and older and 32.8% of high-risk adults 50-74.


It’s clear patients want this, and a product with early evidence is on the shelf. The problem is the conversation in the exam room.


What RSV Does to Older Adults

To many adults, RSV is a children’s illness. The adult numbers say otherwise. The CDC estimates that in the 2024 to 2025 season, there were 190,000 to 350,000 RSV hospitalizations and 10,000 to 23,000 deaths in the United States.


Age accounts for most of the risk. Adults aged 75 and older experienced RSV hospitalizations at a rate of 426.9 per 100,000, the highest rate reported for adults. In a typical year, the CDC estimates hospitalizations for 110,000 to 180,000 adults 50 and older.


The vaccines help curb that outcome. The CDC says vaccination cuts the risk of RSV hospitalization by 75%. A result that good usually sells itself, but here it hasn’t, which says more about how the vaccine gets offered than about how well it works.


You don’t need a dementia signal to justify the shot, and that’s worth remembering because some of the evidence that follows is speculative.


Where RSV and Dementia Converge

RSV causes the most damage in places where many people with dementia live. A study in Rochester, New York, put annual RSV hospitalizations at 117 per 100,000 for adults 65 and older living in the community. In skilled nursing, the figure was 440, and in assisted living, it was 740. Dementia was more common among the facility residents.


A small Paris study went the same way. Among 58 geriatric inpatients with RSV, the median age was 89, and 74% had a neurocognitive disorder. Fifty-eight patients is not conclusive evidence, but the picture matches the facility data.


Dementia also makes any hospital stay more serious. A national study in Taiwan found that dementia increased the risk of severe sepsis by 50% and the risk of dying in the hospital by 28% among hospitalized older adults. Considering life-support treatment eliminated the higher death risk. That study wasn’t about RSV, but it shows the vulnerability these patients bring to any admission.


How eligibility is written also factors in. The CDC’s neurological risk category covers conditions that impair airway clearance or weaken respiratory muscles, such as post-stroke dysphagia or ALS. Dementia isn’t named.


At 75, age settles the question. Below 75, someone must notice the risk factor and write it down. A 68-year-old with early Alzheimer’s who lives at home may qualify only through frailty, dysphagia, or a clinician’s judgment about other risk factors.


That’s a gap, and clinicians who see these patients are the ones qualified to close it.


The Oxford Signal

In June 2025, Oxford researchers published an analysis in npj Vaccines collected from U.S. health records. Their propensity-matched cohorts totaled 436,788 people, most of them 60 or older and largely between 70 and 73. Of those, 35,938 received an RSV vaccine, an estimated 76% of them Arexvy, the adjuvanted RSV vaccine. The comparison group received the flu vaccine.


From three to 18 months after vaccination, people who received the RSV vaccine alone spent 29% more time free of a dementia diagnosis than the flu-vaccine group. For the shingles vaccine alone, the figure was 18%, and for both, it was 37%.


The mechanism is the surprising part. Arexvy and the shingles vaccine Shingrix share an adjuvant called AS01, an ingredient added to strengthen the immune response. The two vaccines performed about the same, so the authors think the adjuvant itself may lower dementia risk. The effect appeared within months, too rapid to be explained by infections that the vaccines prevented.


The practical wrinkle? The finding applies to the AS01-adjuvanted product and says nothing yet about Abrysvo or mResvia. “Get the RSV shot” and “get the shot with the dementia signal” are different conversations, and your patient should know which one you’re having.


What Evidence Can’t Tell You

I would not tell a patient that this vaccine prevents dementia—we cannot say that yet. The finding is an association, and it should remain so in how you say it:


  1. The study was observational. Alzheimer’s Research UK indicated that scientists can’t rule out social and lifestyle differences between groups. Undiagnosed dementia could have skewed results.

  2. Eighteen months is short. The comparison was against people who got the flu shot, not against people who went unvaccinated. Patient Care Online’s study report noted that about 24% of the RSV group may have received a vaccine without AS01.

  3. Better answers are years away. GSK began a study in Finland of its shingles vaccine and new dementia diagnoses in adults 76 and older. Nothing comparable exists for RSV yet.


What Clinicians and Care Teams Can Do Now


None of that uncertainty changes what to do this week. Start with the visits you already have. Check RSV vaccination status at every cognitive assessment visit. For patients under 75, use frailty and facility residence as qualifying factors, and remember that patient attestation is enough to document a risk factor.


Stock the vaccine onsite if possible. In one survey led by GSK researchers, 49.4% of health care professionals estimated that fewer than half of their adult patients would get vaccinated on their recommendation if the vaccine wasn’t available onsite.


Observe who is being missed. In Medicare fee-for-service, RSV vaccine coverage among beneficiaries 75 and older was 38.3% for White beneficiaries and 15.4% for Hispanic beneficiaries as of March 2026. In nursing homes, only 17.9% of residents at facilities that reported RSV data had been vaccinated as of November 2024. That figure is nearly two years old, so check it against your own facility's records.


If a patient or family member asks about dementia research, say what the study found and what it did not. Then make the recommendation on the hospitalization data.


Recommendation

Recommend RSV vaccination for what it has already shown: fewer hospitalizations and fewer deaths. Treat the dementia signal as a reason to keep watching the research. Stop leaving 57% of adults 75 and older unprotected while everyone waits for a dementia vaccine that doesn’t exist yet.


Sources

  1. Montano-Campos JF, Joyce GF, Zissimopoulos JM. Public attitudes about preventive dementia vaccine among US adults. JAMA Netw Open. 2026;9(9):e2634777. doi:10.1001/jamanetworkopen.2026.34777

  2. Centers for Disease Control and Prevention. Weekly RSV vaccination dashboard. RSVVaxView. Updated May 20, 2026. Accessed October 8, 2026. https://www.cdc.gov/rsvvaxview/dashboard/index.html

  3. Silk BJ, Prill MM, Winn AK, et al. Respiratory virus activity—United States, July 1, 2024–June 30, 2025. MMWR Morb Mortal Wkly Rep. 2026;75(6):77-84. doi:10.15585/mmwr.mm7506a2

  4. Centers for Disease Control and Prevention. RSV in adults. Reviewed February 20, 2026. Accessed October 8, 2026. https://www.cdc.gov/rsv/adults/index.html

  5. Centers for Disease Control and Prevention. RSV vaccines for adults [health care provider fact sheet]. July 9, 2025. Accessed October 8, 2026. https://www.cdc.gov/rsv/media/pdfs/2025/12/RSV-in-Adults-HCP-Flyer_July-2025.pdf

  6. Branche AR, Falsey AR, Finelli L, Walsh EE. Residency in long-term care facilities: an important risk factor for respiratory syncytial virus hospitalization. J Infect Dis. 2024;230(5):e1007-e1011. doi:10.1093/infdis/jiae424

  7. Chung VAJ, Baudouin E, Mouna L, et al. Risk factors for mortality in geriatric hospitalized patients with respiratory syncytial virus: the FAMHous study. Article in French. Geriatr Psychol Neuropsychiatr Vieil. 2026;24(1):102-110. doi:10.1684/pnv.2026.1269

  8. Shen HN, Lu CL, Li CY. Dementia increases the risks of acute organ dysfunction, severe sepsis and mortality in hospitalized older patients: a national population-based study. PLoS One. 2012;7(8):e42751. doi:10.1371/journal.pone.0042751

  9. Immunize.org. Ask the experts: RSV vaccine recommendations for adults. Reviewed August 24, 2025. Accessed October 8, 2026. https://www.immunize.org/ask-experts/topic/rsv/vaccine-recs-adults-rsv/

  10. Taquet M, Todd JA, Harrison PJ. Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections. npj Vaccines. 2025;10:130. doi:10.1038/s41541-025-01172-3

  11. Science Media Centre. Expert reaction to study suggesting adjuvants in certain vaccines may be one reason for their association with a reduction in dementia risk. June 25, 2025. Accessed October 8, 2026. https://www.sciencemediacentre.org/expert-reaction-to-study-suggesting-adjuvants-in-certain-vaccines-may-be-one-reason-for-their-association-with-a-reduction-in-dementia-risk/

  12. Adjuvanted vaccine against RSV associated with substantial reduced risk of dementia. Patient Care Online. Accessed October 8, 2026. https://www.patientcareonline.com/view/adjuvanted-vaccine-against-rsv-associated-with-substantial-reduced-risk-of-dementia

  13. GlaxoSmithKline. A study to evaluate the effect of recombinant zoster vaccine on new diagnosis of dementia in an older adult population aged 76 years or older in Finland. ClinicalTrials.gov identifier: NCT07502560. Accessed October 8, 2026. https://clinicaltrials.gov/study/NCT07502560

  14. La EM, Gallington K, Singer D, et al. US healthcare professionals’ knowledge, attitudes, and practices regarding RSV disease and vaccination in adults during the 2024-2025 RSV season. PLoS One. 2026;21(7):e0353266. doi:10.1371/journal.pone.0353266

  15. Reses HE, Segovia G, Dubendris H, et al. Coverage with influenza, respiratory syncytial virus, and COVID-19 vaccines among nursing home residents—National Healthcare Safety Network, United States, November 2024. MMWR Morb Mortal Wkly Rep. 2024;73(46):1052-1057. doi:10.15585/mmwr.mm7346a2


Please note: Claude (Anthropic) assisted as a research tool to summarize background materials for this article. Writing, editing, and fact-checking by the author.




Comments


bottom of page